|
US5986054A
(en)
|
1995-04-28 |
1999-11-16 |
The Hospital For Sick Children, Hsc Research And Development Limited Partnership |
Genetic sequences and proteins related to alzheimer's disease
|
|
DE69635207T2
(de)
*
|
1995-07-07 |
2006-06-22 |
Darwin Molecular Corp. |
Auf Chromosom 1 lokalisiertes Gen dessen Genprodukt mit der Alzheimerschen Krankheit assoziiert ist.
|
|
WO1997003999A1
(en)
*
|
1995-07-18 |
1997-02-06 |
Washington University School Of Medicine |
Mutant s182 genes
|
|
US5985564A
(en)
*
|
1995-08-16 |
1999-11-16 |
President And Fellows Of Harvard College |
Assay for identifying agents that inhibit chromosome non-disjunction
|
|
US6248555B1
(en)
|
1995-08-31 |
2001-06-19 |
The General Hospital Corporation |
Genetic alterations related to familial alzheimer's disease
|
|
CA2233297A1
(en)
*
|
1995-09-27 |
1997-04-03 |
Iva Greenwald |
Identification of sel-12 and uses thereof
|
|
ZA968898B
(en)
*
|
1995-10-25 |
1998-03-30 |
Washington University Of Medic |
Method for elucidation and detection of polymorphisms, splice variants and proximal coding mutations using intronic sequences of the mutations Alzheimer's S182 gene.
|
|
JPH10327897A
(ja)
*
|
1996-01-19 |
1998-12-15 |
Washington Univ |
プレセニリン−１遺伝子の配列を用いる疾患の診断および予後診断
|
|
WO1997027296A1
(en)
*
|
1996-01-26 |
1997-07-31 |
Hsc Research And Development Limited Partnership |
Nucleic acids and proteins related to alzheimer's disease, and uses therefor
|
|
WO1997038133A1
(en)
*
|
1996-04-04 |
1997-10-16 |
University Of South Florida |
Variant presenilin-2 genes
|
|
WO1997046678A1
(en)
*
|
1996-06-06 |
1997-12-11 |
Bayer Corporation |
Nucleic acids and polypeptides related to presenilin
|
|
EP0811695A3
(en)
*
|
1996-06-06 |
1998-07-29 |
Washington University |
Mutant S182(PS-1) genes
|
|
EP0814157A3
(en)
*
|
1996-06-18 |
1998-01-07 |
Smithkline Beecham Corporation |
Diagnostic marker for variants of presenilin genes associated with Alzheimers Disease and Familial Adult Onset Alzheimers Disease
|
|
JP2000516087A
(ja)
*
|
1996-07-05 |
2000-12-05 |
ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント |
アルツハイマー病に関連する遺伝子配列およびタンパク質、ならびにその使用
|
|
WO1998025142A1
(en)
|
1996-12-02 |
1998-06-11 |
The Brigham And Women's Hospital, Inc. |
Alarm related peptides and nucleic acids and diagnosis using them
|
|
US6121045A
(en)
*
|
1997-04-04 |
2000-09-19 |
Millennium Biotherapeutics, Inc. |
Human Delta3 nucleic acid molecules
|
|
US6376239B1
(en)
*
|
1997-04-04 |
2002-04-23 |
Elegene Gmbh |
DNA molecules comprising a promoter capable of conferring expression of a heterologous DNA sequence
|
|
WO1998047917A2
(en)
*
|
1997-04-24 |
1998-10-29 |
The General Hospital Corporation |
A PURIFIED 20 kDa PRESENILIN 2 C-TERMINAL FRAGMENT AND METHODS OF SCREENING FOR COMPOUNDS THAT INHIBIT PROTEOLYSIS OF PRESENILIN 2
|
|
CA2290039A1
(en)
*
|
1997-05-14 |
1998-11-19 |
Merck & Co., Inc. |
Transgenic animal expressing non-native wild-type and familial alzheimer's disease mutant presenilin 1 protein on native presenilin 1 null background
|
|
ES2128265B1
(es)
*
|
1997-06-04 |
2000-03-01 |
Euroespes S A |
Kit genetico para la caracterizacion molecular de la enfermedad de alzheimer.
|
|
US7923015B2
(en)
*
|
1997-08-14 |
2011-04-12 |
Institut Pasteur |
Methods for direct visualization of active synapses
|
|
US7923216B2
(en)
*
|
1997-08-14 |
2011-04-12 |
Institut Pasteur |
In vivo modulation of neuronal transport
|
|
US20100081197A1
(en)
*
|
1997-08-14 |
2010-04-01 |
Sylvie Roux |
In vivo modulation of neuronal transport
|
|
ATE352558T1
(de)
*
|
1997-08-14 |
2007-02-15 |
Pasteur Institut |
Hybdride tetanustoxinproteine die rückwirkend und transsynatisch ins zns migrieren
|
|
US6284944B1
(en)
*
|
1997-08-29 |
2001-09-04 |
Cephalon, Inc, |
Gene-targeted non-human mammal with a human fad presenilin mutation and generational offspring
|
|
US6255473B1
(en)
*
|
1997-08-29 |
2001-07-03 |
Duke University |
Presenilin-1 gene promoter
|
|
FR2768346B1
(fr)
|
1997-09-15 |
2002-04-19 |
Fond Jean Dausset Ceph |
Compose assurant l'inhibition de la preseniline 1 pour la preparation d'un medicament et agent de diagnostic
|
|
JP2001521043A
(ja)
*
|
1997-10-24 |
2001-11-06 |
アバンテイス・フアルマ・エス・アー |
プレセニリンとβ−アミロイドペプチドまたはその前駆体との相互作用を阻害し得るペプチド
|
|
FR2770217B1
(fr)
*
|
1997-10-24 |
2001-12-07 |
Rhone Poulenc Rorer Sa |
Peptides capables d'inhiber l'interaction entre les presenilines et le precurseur du peptide b-amyloide et/ou le peptide b-amyloide
|
|
EP1044605B1
(en)
*
|
1998-01-08 |
2007-04-25 |
Daiichi Pharmaceutical Co., Ltd. |
Gene mutant animals
|
|
WO1999035501A1
(en)
*
|
1998-01-09 |
1999-07-15 |
The Governing Council Of The University Of Toronto |
Presenilin protein interactions
|
|
EP1849477A1
(en)
*
|
1998-02-25 |
2007-10-31 |
THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY |
Use of skin penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response induced by ADP-ribosylating exotoxin
|
|
DE69940906D1
(de)
*
|
1998-05-21 |
2009-07-02 |
Mitsubishi Tanabe Pharma Corp |
Verfahren zur untersuchung von krankheiten des zentralen nervensystems und verfahren zum aufsuchen von arzneimitteln
|
|
AR020329A1
(es)
*
|
1998-07-09 |
2002-05-08 |
Boehringer Ingelheim Pharma |
UNA SUSTANCIA, EN PARTICULAR UNA RIBOZIMA, CAPAZ DE INHIBIR LA EXPRESION DE PRESENILINA 2, UNA MOLECULA DE DNA RECOMBINANTE QUE CODIFICA DICHA RIBOZIMA, UNVECTOR RECOMBINANTE QUE COMPRENDE EL cDNA CORRESPONDIENTE A DICHA RIBOZIMA, UNA CELULA HOSPEDADORA QUE COMPRENDE DICHO VECTOR RECOMBINANTE, UNA C
|
|
JP2002520055A
(ja)
*
|
1998-07-16 |
2002-07-09 |
インサイト・ファーマスーティカルズ・インコーポレイテッド |
ヒトプレセニリン関連タンパク質
|
|
US6797480B1
(en)
|
1998-10-05 |
2004-09-28 |
University Of Connecticut Health Center |
Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents
|
|
US6723557B1
(en)
|
1999-01-06 |
2004-04-20 |
California Institute Of Technology |
Caenorhabditis elegans LOV-1 gene
|
|
US6783982B1
(en)
|
1999-02-12 |
2004-08-31 |
The Governing Council Of The University Of Toronto |
Proteins related to neuronal regeneration and uses thereof
|
|
US6812337B1
(en)
*
|
1999-04-01 |
2004-11-02 |
The Governing Council Of The University Of Toronto |
Presenilin associated membrane protein and uses thereof
|
|
WO2000059297A2
(en)
*
|
1999-04-06 |
2000-10-12 |
Harrington Arthritis Research Center |
Methods for tracking the progression of alzheimer's disease and identifying treatments using transgenic mice
|
|
US6890726B1
(en)
|
1999-04-06 |
2005-05-10 |
Oklahoma Medical Research Foundation |
Method for selecting recombinase variants with altered specificity
|
|
US20030131364A1
(en)
*
|
1999-04-27 |
2003-07-10 |
Karen Duff |
Method for producing transgenic animal models with modulated phenotype and animals produced therefrom
|
|
AU6265600A
(en)
*
|
1999-06-22 |
2001-01-09 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Method for detection of early-onset alzheimer's disease
|
|
EP1194449B1
(en)
*
|
1999-06-28 |
2010-09-22 |
Oklahoma Medical Research Foundation |
Inhibitors of memapsin 2 and use thereof
|
|
US20020049303A1
(en)
*
|
1999-06-28 |
2002-04-25 |
Tang Jordan J. N. |
Catalytically active recombinant memapsin and methods of use thereof
|
|
FR2798821B1
(fr)
*
|
1999-09-27 |
2001-10-26 |
Aventis Pharma Sa |
Animal transgenique exprimant une forme multi-mutee de la preseniline 1
|
|
AU2001227960A1
(en)
*
|
2000-01-21 |
2001-07-31 |
University Of Connecticut Health Center |
Heat shock/stress protein complexes as vaccines against neurodegenerative disorders
|
|
IL151828A0
(en)
|
2000-04-03 |
2003-04-10 |
Bristol Myers Squibb Pharma Co |
Proteins having gamma-secretase activity and methods for isolating the same and methods detecting said activity
|
|
AU2001264950A1
(en)
*
|
2000-05-26 |
2001-12-11 |
Duke University |
Methods of screening for parkinson's disease
|
|
US6930169B2
(en)
*
|
2000-06-12 |
2005-08-16 |
University Of Baltimore Biotechnology Institute |
Method of controlling the binding of calmyrin to presenilin
|
|
US7371920B2
(en)
|
2000-06-20 |
2008-05-13 |
The Governing Council Of The University Of Toronto |
Transgenic mouse model of neurodegenerative disorders
|
|
AU2001273661A1
(en)
*
|
2000-06-30 |
2002-01-14 |
Duke University |
Methods of screening for alzheimer's disease
|
|
DE10032709A1
(de)
*
|
2000-07-07 |
2002-01-24 |
Boehringer Ingelheim Pharma |
Aspartyl-Protease
|
|
WO2002005634A2
(en)
|
2000-07-13 |
2002-01-24 |
University Of South Florida |
Transgenic animal and methods
|
|
JP2002142765A
(ja)
*
|
2000-07-14 |
2002-05-21 |
Tosoh Corp |
新規ゲノム解析法
|
|
WO2002014546A1
(en)
*
|
2000-08-16 |
2002-02-21 |
Markus Fritzsche |
Use of microbial dna sequences for the identification of human diseases
|
|
AU2001287448A1
(en)
*
|
2000-09-01 |
2002-03-13 |
The Governing Council Of The University Of Toronto |
Proteins related to schizophrenia and uses thereof
|
|
US6900367B2
(en)
*
|
2000-09-29 |
2005-05-31 |
Novartis |
Transgenic Drosophila melanogaster expressing a β42 in the eye
|
|
US6495335B2
(en)
*
|
2000-12-07 |
2002-12-17 |
Mario Chojkier |
Compositions and methods for diagnosing alzheimer's disease
|
|
US20040121947A1
(en)
*
|
2000-12-28 |
2004-06-24 |
Oklahoma Medical Research Foundation |
Compounds which inhibit beta-secretase activity and methods of use thereof
|
|
US6815175B2
(en)
|
2001-03-16 |
2004-11-09 |
Cornell Research Foundation, Inc. |
Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
|
|
US20030073608A1
(en)
*
|
2001-04-10 |
2003-04-17 |
Woolf Nancy J. |
Process for treating disease
|
|
GB2375771A
(en)
*
|
2001-05-24 |
2002-11-27 |
Univ Leeds |
Decellularisation of tissue implant material
|
|
JP2003012548A
(ja)
*
|
2001-06-27 |
2003-01-15 |
Japan Science & Technology Corp |
医薬組成物
|
|
EP2354793B1
(en)
|
2001-08-14 |
2016-06-22 |
Sentigen Biosciences, Inc. |
Nucleic acids and proteins of insect OR83B odorant receptor genes and uses thereof
|
|
US20060234944A1
(en)
*
|
2001-10-23 |
2006-10-19 |
Oklahoma Medical Reseach Foundation |
Beta-secretase inhibitors and methods of use
|
|
EP1448218A4
(en)
*
|
2001-10-23 |
2009-01-14 |
Oklahoma Med Res Found |
BETA SECRETASE INHIBITORS AND METHOD OF USE
|
|
EP1456668B1
(en)
*
|
2001-12-05 |
2007-05-02 |
Sense Proteomic Limited |
Protein arrays for allelic variants and uses thereof
|
|
AU2002359781A1
(en)
*
|
2001-12-20 |
2003-07-09 |
The Regents Of The University Of California |
Triple transgenic mouse model of alzheimer's disease
|
|
US20040014109A1
(en)
*
|
2002-05-23 |
2004-01-22 |
Pericak-Vance Margaret A. |
Methods and genes associated with screening assays for age at onset and common neurodegenerative diseases
|
|
WO2004005921A1
(en)
*
|
2002-07-05 |
2004-01-15 |
Evotec Neurosciences Gmbh |
Diagnostic and therapeutic use of tb2 gene and protein for neurodegenerative diseases
|
|
US20060183117A1
(en)
*
|
2002-07-08 |
2006-08-17 |
Pericak-Vance Margaret A |
Screening for alzheimer's disease
|
|
US20040076606A1
(en)
*
|
2002-09-14 |
2004-04-22 |
Ming-Shi Chang |
Methods of modulating inflammation by administration of interleukin-19 and inhibitors of IL-19 binding
|
|
US7022481B2
(en)
|
2002-12-19 |
2006-04-04 |
Rosetta Inpharmatics Llc |
Methods of using glucan synthase pathway reporter genes to screen for antifungal compounds
|
|
US20060246437A1
(en)
*
|
2003-07-11 |
2006-11-02 |
Pericak-Vance Margaret A |
Genetic susceptibility genes for asthma and atopy and asthma-related and atopic-related phenotypes
|
|
US20060068428A1
(en)
*
|
2003-11-03 |
2006-03-30 |
Duke University |
Identification of genetic markers associated with parkinson disease
|
|
US20050191652A1
(en)
*
|
2003-11-03 |
2005-09-01 |
Vance Jeffery M. |
Identification of genetic forms of a gene that leads to high risk for parkinson disease
|
|
WO2005075684A2
(en)
*
|
2004-01-30 |
2005-08-18 |
Xenoport, Inc. |
Use of organic anion transporter b in screens for candidate substrates for crossing the blood brain barrier
|
|
US20050170392A1
(en)
*
|
2004-01-30 |
2005-08-04 |
Xenoport, Inc. |
OAT3 transporters expressed in blood brain barrier cells
|
|
SE0400707D0
(sv)
|
2004-03-22 |
2004-03-22 |
Bioarctic Neuroscience Ab |
Transgenic animal model
|
|
US7790390B2
(en)
*
|
2004-10-27 |
2010-09-07 |
Duke University |
Methods for identifying an individual at increased risk of developing coronary artery disease
|
|
US7807465B2
(en)
*
|
2004-10-27 |
2010-10-05 |
Duke University |
Methods for identifying an individual at increased risk of developing coronary artery disease
|
|
US7833725B2
(en)
*
|
2005-01-06 |
2010-11-16 |
President And Fellows Of Harvard College |
Mass spectrometric methods and products
|
|
US20070092449A1
(en)
*
|
2005-04-05 |
2007-04-26 |
Rafael Vazquez-Martinez |
Methods for direct visualization of active synapses
|
|
US20070148661A1
(en)
*
|
2005-07-19 |
2007-06-28 |
Duke University |
LSAMP Gene Associated With Cardiovascular Disease
|
|
US7704696B2
(en)
*
|
2005-07-29 |
2010-04-27 |
Xenoport, Inc. |
Screening of compounds for OCTN2 transporter activity
|
|
US7670782B2
(en)
*
|
2005-07-29 |
2010-03-02 |
Xenoport, Inc. |
Screening of compounds for CAT1 transporter activity
|
|
US7691584B2
(en)
*
|
2005-07-29 |
2010-04-06 |
Xenoport, Inc. |
Screening of compounds for OCT3 transporter activity
|
|
US7704695B2
(en)
*
|
2005-07-29 |
2010-04-27 |
Xenoport, Inc. |
Screening of compounds for BGT1 transporter activity
|
|
WO2007016159A2
(en)
*
|
2005-07-29 |
2007-02-08 |
Xenoport, Inc. |
Gat2 transporters expressed in blood brain barrier cells
|
|
WO2007021886A2
(en)
*
|
2005-08-10 |
2007-02-22 |
Oklahoma Medical Research Foundation |
Truncated memapsin 2 for use for treating alzheimer's disease
|
|
US20090226420A1
(en)
*
|
2005-11-10 |
2009-09-10 |
Elizabeth Hauser |
Methods of Determining the Risk of Developing Coronary Artery Disease
|
|
US8852585B2
(en)
|
2006-01-30 |
2014-10-07 |
Grifols Therapeutics Inc. |
Method of treatment and prophylaxis of diseases related to amyloid deposition using IgM
|
|
WO2007092861A2
(en)
*
|
2006-02-06 |
2007-08-16 |
Elan Pharmaceuticals, Inc. |
Inhibitors specific of presenilin-1 and their uses
|
|
WO2007123680A2
(en)
|
2006-03-31 |
2007-11-01 |
The Regents Of The University Of California |
Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory
|
|
US8129334B2
(en)
|
2006-03-31 |
2012-03-06 |
The Regents Of The University Of California |
Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
|
|
US7771741B2
(en)
*
|
2006-05-01 |
2010-08-10 |
Warsaw Orthopedic, Inc |
Demineralized bone matrix devices
|
|
EP2024503A2
(en)
*
|
2006-05-01 |
2009-02-18 |
Aarhus Universitet |
An animal model and a method for producing an animal model
|
|
EP2134846B1
(en)
*
|
2007-03-07 |
2018-08-08 |
Aarhus Universitet |
Transgenic pig as a model of alzheimer's disease
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
US9068006B2
(en)
|
2010-08-25 |
2015-06-30 |
President And Fellows Of Harvard College |
Glycated CD59 peptides, their preparation, and uses thereof
|
|
EP2857499A1
(en)
|
2010-10-01 |
2015-04-08 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
US20140193341A1
(en)
*
|
2011-01-19 |
2014-07-10 |
Asa Abeliovich |
Human induced neuronal cells
|
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
WO2012178183A1
(en)
*
|
2011-06-24 |
2012-12-27 |
Board Of Regents, The University Of Texas System |
Human age-related neurodegenerative nematode model and methods
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
PT3682905T
(pt)
|
2011-10-03 |
2022-04-07 |
Modernatx Inc |
Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
|
|
EP2791159A4
(en)
*
|
2011-12-14 |
2015-10-14 |
Moderna Therapeutics Inc |
MODIFIED NUCLEIC ACIDS AND ACUTE TREATMENT USES THEREOF
|
|
ES2923757T3
(es)
|
2011-12-16 |
2022-09-30 |
Modernatx Inc |
Composiciones de ARNm modificado
|
|
WO2013151664A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
PT2922554T
(pt)
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Arn modificado nas porções terminais
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
ES2530141B1
(es)
*
|
2013-08-26 |
2016-01-15 |
Juan Carlos GALLAR RUIZ |
Péptido útil como diana farmacológica para el cribado de moléculas para el tratamiento y/o prevención de la enfermedad de Alzheimer, anticuerpo frente al mismo y uso del anticuerpo para el tratamiento y/o prevención de dicha enfermedad.
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
EP3347486A4
(en)
|
2015-09-09 |
2019-06-19 |
The Trustees of Columbia University in the City of New York |
REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
|
|
CN111201030B
(zh)
|
2017-07-25 |
2024-11-01 |
真和制药有限公司 |
通过阻断tim-3和其配体的相互作用治疗癌症
|
|
ES2817910T3
(es)
*
|
2017-08-04 |
2021-04-08 |
Alzheimur 2012 S L |
Uso de un anticuerpo antipresenilina para la prevención y/o tratamiento del cáncer
|
|
AU2019272848A1
(en)
*
|
2018-05-22 |
2020-12-03 |
The Brigham And Women's Hospital, Inc. |
Gene therapy for alzheimer's disease
|
|
KR20210124308A
(ko)
|
2019-01-30 |
2021-10-14 |
트루바인딩 아이엔씨. |
항-gal3 항체 및 이의 용도
|
|
CA3141712A1
(en)
*
|
2019-05-24 |
2020-12-03 |
The Brigham And Women's Hospital, Inc. |
Gene therapy for alzheimer's disease
|
|
AU2020393917A1
(en)
|
2019-11-29 |
2022-06-23 |
Paros Bio, Inc. |
Gene therapy for neurodegenerative disorders
|
|
MX2022014786A
(es)
|
2020-05-26 |
2023-01-16 |
Truebinding Inc |
Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
|
|
KR102584857B1
(ko)
*
|
2020-09-23 |
2023-10-06 |
재단법인대구경북과학기술원 |
알츠하이머 동물모델 및 이의 용도
|
|
KR20230009140A
(ko)
*
|
2021-07-08 |
2023-01-17 |
주식회사 엠케이바이오텍 |
Human mutant Presenilin-1 발현 인지장애 모델 개의 생산
|